Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design
about
Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.Viral evasion and challenges of hepatitis C virus vaccine development.Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422.The dynamic properties of the Hepatitis C Virus E2 envelope protein unraveled by molecular dynamics.Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope.Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages.Computational Modeling of Hepatitis C Virus Envelope Glycoprotein Structure and Recognition.The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein.Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data.
P2860
Q35912053-1204F47E-A601-4342-B016-51F074D4B674Q36288404-7D8710C5-543B-4598-A875-8306B02F87C7Q37417839-152764EF-6F7B-4F04-A921-73C96BE29D6AQ37417999-B49CDE65-6F1D-45AD-8600-D4B3D5BEC645Q37512845-8EC85DEF-1B0D-4266-8F13-81FE7D591222Q38961608-BB73CC33-87D2-47EB-A59C-BF6307FA1F77Q39062848-97332BDC-4705-471A-846A-3B1B364A9629Q39923648-9D41A0E7-60B9-4E6D-9678-C4BBC5AC713EQ40088796-3F2CBD25-BEED-436B-A503-489BDA94470AQ40634075-F0D28262-BA7F-483F-8766-4493905FD7BCQ47238536-BF80873F-0DE4-4E1A-9B0E-4072182BA832Q47548062-B8F03EE4-5AF1-45C8-8D11-1F41D635C437Q47569740-EB45464C-D4E3-416D-BD5A-F1014D63A532Q50005891-01F6005C-C8E3-42BD-A03B-5F59FBE45C51Q55003572-4DD55776-7D01-4473-92D0-1AA0268E3291Q55299977-8DDE3772-C178-4D23-B59F-B3AF6B3E6885Q55657826-F7BA37E5-276C-4413-8B78-D45EF96EB0A9
P2860
Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Capitalizing on knowledge of h ...... es for rational vaccine design
@ast
Capitalizing on knowledge of h ...... es for rational vaccine design
@en
type
label
Capitalizing on knowledge of h ...... es for rational vaccine design
@ast
Capitalizing on knowledge of h ...... es for rational vaccine design
@en
prefLabel
Capitalizing on knowledge of h ...... es for rational vaccine design
@ast
Capitalizing on knowledge of h ...... es for rational vaccine design
@en
P2093
P2860
P1476
Capitalizing on knowledge of h ...... es for rational vaccine design
@en
P2093
Kelli N Jackson
Leopold Kong
Mansun Law
P2860
P304
P356
10.1016/J.COVIRO.2015.04.001
P577
2015-04-29T00:00:00Z